Diabetes

Continuous Glucose Monitors (CGMs): How They Work, Benefits, and Limits

A comprehensive guide to continuous glucose monitors — how they work, who benefits, accuracy considerations, cost, data privacy, and practical tips for getting the most from your CGM.

Updated: 8 min read

Continuous Glucose Monitors (CGMs): How They Work, Benefits, and Limits

A continuous glucose monitor (CGM) is a small wearable device that automatically measures glucose levels throughout the day and night. Unlike a finger-prick meter, which gives a single snapshot, a CGM streams readings every one to five minutes — showing trends, generating alerts, and building a continuous picture of how glucose rises and falls in response to food, activity, sleep, and stress.

CGMs were initially designed for people with Type 1 diabetes, where hypoglycaemia risk and insulin dependence are constant. They are now widely used in Type 2 diabetes, increasingly relevant for prediabetes, and available to general consumers as wellness tools.

How CGMs Work

A CGM consists of three components:

  1. Sensor — A small, flexible filament inserted just under the skin (typically on the upper arm or abdomen). It measures glucose in the interstitial fluid — the fluid surrounding cells — rather than directly in the blood.
  2. Transmitter — Sends glucose readings wirelessly, usually via Bluetooth, to a display device or smartphone app. Some systems combine the sensor and transmitter in a single unit.
  3. Receiver or app — Displays real-time readings, trend arrows (indicating whether glucose is rising, stable, or falling, and how fast), and stores data for review.

Interstitial vs blood glucose: Because CGMs measure interstitial fluid, readings typically lag 5–15 minutes behind blood glucose, particularly during rapid changes. This is clinically acceptable for most monitoring purposes, but matters in specific situations — see accuracy section below.

Most CGMs are factory-calibrated and do not require regular finger-prick calibration, though some older devices did. Sensors are typically replaced every 10–15 days.

Key Benefits

24/7 visibility without repeated finger pricks A CGM provides a continuous data stream rather than isolated snapshots. This is particularly valuable overnight, when undetected hypoglycaemia is a recognised risk — especially in Type 1 diabetes.

Trend arrows Knowing your glucose is 7.5 mmol/L and rising steeply is clinically different from knowing it is 7.5 mmol/L and stable. Trend arrows allow more precise insulin dosing, meal timing, and exercise decisions.

Alerts and alarms CGMs can be set to alarm when glucose drops below or rises above set thresholds. Low glucose alerts are a significant safety feature — particularly for people with hypoglycaemia unawareness, who may not feel the usual warning symptoms.

Pattern recognition CGM data over days and weeks reveals patterns that isolated readings cannot — recurring post-meal spikes, dawn phenomenon, exercise-related dips, and the impact of stress or illness. This data drives more targeted clinical decisions.

Enabling automated insulin delivery (AID) Modern CGMs integrated with compatible insulin pumps form “closed loop” systems that automatically adjust basal insulin delivery based on real-time glucose readings. These systems have substantially improved glucose outcomes and quality of life for many people with Type 1 diabetes.

Limitations

Interstitial lag During rapid glucose changes — intense exercise, treatment of a severe hypo, or a large post-meal spike — the interstitial reading can lag significantly behind blood glucose. In these situations, a finger-prick confirmation is appropriate.

Sensor warm-up period Most CGMs require a warm-up period of one to two hours after insertion before readings are reliable. Treat the warm-up period as a transition — do not make critical dosing decisions during this time without confirming with a meter.

Compression artefacts Lying on a sensor (particularly overnight) can restrict interstitial fluid flow and generate falsely low readings. If a low alarm wakes you but you feel well, sit up, move, and recheck — or confirm with a finger prick.

Adhesion and skin reactions The adhesive patches required to hold sensors in place can cause skin irritation, particularly in people with sensitive skin or when sites are not rotated. Over-patches and skin preparation products can help.

Sensor failures and inaccuracies Occasional sensor errors are part of CGM use. Treat the device as a clinical tool that requires interpretation, not an infallible source.

Accuracy Considerations

CGM accuracy is measured by Mean Absolute Relative Difference (MARD) — the average percentage difference between CGM readings and a reference blood glucose measurement. Current generation CGMs from major manufacturers typically achieve MARD values of 7–10%, which is clinically acceptable for most monitoring purposes.

When to confirm with a finger-prick meter:

  • Symptoms (sweating, tremor, confusion) that do not match the CGM reading
  • During or immediately after intense exercise
  • Within the first 12–24 hours after inserting a new sensor
  • Before driving if there is any uncertainty about the reading
  • When symptoms of severe hypoglycaemia are present — treat first, check meter second

ISO 15197 standards require that 95% of blood glucose meter readings fall within ±15 mg/dL of the reference value at low glucose concentrations and within ±15% at higher concentrations. CGM accuracy standards are evolving; newer regulations are progressively tightening requirements.

Cost and Accessibility

CGM costs vary substantially by country, product, and whether subsidy or insurance coverage applies.

Subsidised access: In many countries, CGMs are funded or heavily subsidised for people with Type 1 diabetes. Coverage for Type 2 diabetes is expanding but remains inconsistent — some systems fund CGMs only for those on insulin, others apply broader criteria.

Consumer CGMs: A growing market of prescription-free, consumer-facing CGMs (such as Abbott Lingo and Dexcom Stelo) targets people without diabetes who want metabolic insight. These typically cost less than clinical-grade devices but may offer fewer clinical features.

Out-of-pocket costs: Without subsidy, annual CGM costs for ongoing sensor use can be substantial — ranging from several hundred to several thousand dollars depending on the device and country.

Speak with your care team or a diabetes specialist nurse about what is covered in your region, and whether your specific situation meets the criteria for publicly funded access.

Privacy and Data Considerations

CGMs generate a significant volume of personal health data. Understanding how that data is stored and used is increasingly important.

  • Cloud storage: Most CGM systems upload data to manufacturer cloud platforms. Review the privacy policy of your specific device and app.
  • Third-party access: Nightscout, Dexcom CLARITY, LibreView, and similar platforms allow sharing of CGM data with clinicians, family members, or caregivers. Understand who has access to your data and under what conditions.
  • Data security: As with any connected health device, ensure your app and associated accounts use strong passwords and two-factor authentication where available.
  • Consumer devices: For non-prescription CGMs marketed as wellness products, data policies may differ from those of regulated medical devices. Read terms carefully.

Your glucose data is sensitive health information. Use platforms and sharing settings intentionally, not by default.

Risks / Considerations

  • Alarm fatigue: Excessive or poorly calibrated alerts can be ignored over time, reducing their safety value. Set alert thresholds thoughtfully in consultation with your diabetes care team.
  • Over-reliance: CGM is a tool, not a substitute for clinical judgement. Do not make major treatment changes based on CGM data alone without guidance from your care team.
  • Skin and insertion site care: Rotate sites regularly, inspect for redness or swelling, and follow manufacturer guidance on clean technique.
  • Interference: Some medications (notably high-dose paracetamol/acetaminophen with older devices) and certain clinical settings (MRI, CT scanning) can interfere with sensor function. Check manufacturer guidance.
  • Not a diagnosis: CGM data, including pattern reports, does not replace formal diagnostic tests such as HbA1c or fasting plasma glucose for diagnosing diabetes or prediabetes.

Frequently Asked Questions

Q: Who benefits most from a CGM? A: People with Type 1 diabetes gain the most established clinical benefit — CGMs reduce severe hypoglycaemia, improve time in range, and enable automated insulin delivery. People with insulin-treated Type 2 diabetes, those with hypoglycaemia unawareness, and people with prediabetes seeking to understand their glucose responses to food and lifestyle also derive meaningful benefit.

Q: Can I use a CGM to find out if I have prediabetes? A: A CGM can reveal glucose patterns suggestive of insulin resistance or elevated post-meal responses, but it is not a diagnostic tool. Formal diagnosis of prediabetes requires a blood test — fasting plasma glucose, HbA1c, or an oral glucose tolerance test. If your CGM data concerns you, speak with your doctor about formal screening.

Q: How long does a CGM sensor last? A: Most sensors are designed to last 10–15 days, depending on the device. Abbott FreeStyle Libre 2 and 3 sensors last 14 days; Dexcom G7 sensors last 10 days. Some users extend sensor wear (a practice not endorsed by manufacturers), which affects accuracy and reliability.

Q: Does a CGM hurt? A: Sensor insertion involves a small, brief needle used only to insert the filament. Most people describe the sensation as minimal — less discomfort than a standard finger prick. The filament itself stays under the skin but is flexible and generally not felt during wear.

Q: Are CGMs waterproof? A: Most modern CGMs are water-resistant and can be worn while swimming, showering, or sweating. Check the IP (Ingress Protection) rating for your specific device, as waterproofing standards vary.

Note: This guide is for educational purposes and is not a substitute for advice from your diabetes care team. CGM suitability, targets, and alert settings should be discussed with your clinician.